Published in J Diabetes Complications on April 23, 2009
Comparison of Insulins Aspart and Lispro in Insulin Pumps | NCT00461331
Randomized trial of infusion set function: steel versus teflon. Diabetes Technol Ther (2013) 2.15
Insulin infusion set: the Achilles heel of continuous subcutaneous insulin infusion. J Diabetes Sci Technol (2012) 1.58
CSII: Longer Catheter Usage Time, a Reasonable Goal. J Diabetes Sci Technol (2016) 0.97
Nonmetabolic complications of continuous subcutaneous insulin infusion: a patient survey. Diabetes Technol Ther (2013) 0.90
Intradermal insulin infusion achieves faster insulin action than subcutaneous infusion for 3-day wear. Drug Deliv Transl Res (2015) 0.89
Continuous subcutaneous insulin infusion in diabetes: patient populations, safety, efficacy, and pharmacoeconomics. Diabetes Metab Res Rev (2015) 0.88
Reduced Silent Occlusions with a Novel Catheter Infusion Set (BD FlowSmart): Results from Two Open-Label Comparative Studies. Diabetes Technol Ther (2015) 0.83
Cumulative clinical experience with use of insulin lispro: critical appraisal, role in therapy, and patient considerations. Diabetes Metab Syndr Obes (2012) 0.80
Duration of Infusion Set Survival in Lipohypertrophy Versus Nonlipohypertrophied Tissue in Patients with Type 1 Diabetes. Diabetes Technol Ther (2016) 0.80
Insulin Pump and CGM Usage in the United States and Germany: Results of a Real-World Survey With 985 Subjects. J Diabetes Sci Technol (2015) 0.79
The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med (1993) 102.56
Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA (2006) 11.78
Measurement of F(2)-isoprostanes as an index of oxidative stress in vivo. Free Radic Biol Med (2000) 3.53
Recent advances in treatment of youth with Type 1 diabetes: better care through technology. Diabet Med (2001) 3.13
Missed insulin meal boluses and elevated hemoglobin A1c levels in children receiving insulin pump therapy. Pediatrics (2004) 2.65
A randomized trial of continuous subcutaneous insulin infusion and intensive injection therapy in type 1 diabetes for patients with long-standing poor glycemic control. Diabetes Care (2002) 2.51
Acute complications associated with insulin infusion pump therapy. Report of experience with 161 patients. JAMA (1984) 2.47
Continuous subcutaneous insulin infusion at 25 years: evidence base for the expanding use of insulin pump therapy in type 1 diabetes. Diabetes Care (2002) 2.26
Factors associated with glycemic control. A cross-sectional nationwide study in 2,579 French children with type 1 diabetes. The French Pediatric Diabetes Group. Diabetes Care (1998) 2.23
Continuous subcutaneous insulin infusion (CSII) of insulin aspart versus multiple daily injection of insulin aspart/insulin glargine in type 1 diabetic patients previously treated with CSII. Diabetes Care (2005) 1.59
Safety of insulin glulisine when given by continuous subcutaneous infusion using an external pump in patients with type 1 diabetes. Horm Metab Res (2006) 1.56
Clinical significance, pathogenesis, and management of postprandial hyperglycemia. Arch Intern Med (2003) 1.55
Serum levels of non-carboxymethyllysine advanced glycation endproducts are correlated to severity of microvascular complications in patients with Type 1 diabetes. J Diabetes Complications (2002) 1.26
Pharmacokinetics of continuous subcutaneous insulin infusion. Diabetologia (1983) 1.25
Continuous subcutaneous insulin infusion: a comprehensive review of insulin pump therapy. Arch Intern Med (2001) 1.22
HPLC-atmospheric pressure chemical ionization MS/MS for quantification of 15-F2t-isoprostane in human urine and plasma. Clin Chem (2007) 1.22
Prevalence and correlates of post-prandial hyperglycaemia in a large sample of patients with type 2 diabetes mellitus. Diabetologia (2006) 1.19
Determinants of glycaemic control in type 1 diabetes during intensified therapy with multiple daily insulin injections or continuous subcutaneous insulin infusion: importance of blood glucose variability. Diabetes Metab Res Rev (2006) 1.05
Comparison of in vitro stability for insulin aspart and insulin glulisine during simulated use in insulin pumps. Diabetes Technol Ther (2007) 1.01
Toxic-shock syndrome in a patient using a continuous subcutaneous insulin infusion pump--Idaho. MMWR Morb Mortal Wkly Rep (1983) 0.98
Oxidant stress, immune dysregulation, and vascular function in type I diabetes. Antioxid Redox Signal (2007) 0.93
Reemergence of insulin pump therapy in the 1990s. South Med J (2000) 0.86
F2 isoprostane is already increased at the onset of type 1 diabetes mellitus: effect of glycemic control. Metabolism (2004) 0.84
Short-term hyperglycemic dysregulation in patients with type 1 diabetes does not change myocardial triglyceride content or myocardial function. Diabetes Care (2008) 0.83
Increased Nepsilon-(carboxymethyl)-lysine levels in cerebral blood vessels of diabetic patients and in a (streptozotocin-treated) rat model of diabetes mellitus. Eur J Endocrinol (2008) 0.83
Cutaneous complications of chronic continuous subcutaneous insulin infusion therapy. Diabetes Care (1982) 0.81
Quality control of intensified insulin therapy: HbA1 versus blood glucose. Horm Metab Res (1994) 0.78
Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med (2010) 5.46
The metabolic syndrome and chronic kidney disease in U.S. adults. Ann Intern Med (2004) 5.45
Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Circulation (2006) 4.61
Effect of nateglinide on the incidence of diabetes and cardiovascular events. N Engl J Med (2010) 4.38
Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Diabetes Care (2007) 4.30
The effects of salsalate on glycemic control in patients with type 2 diabetes: a randomized trial. Ann Intern Med (2010) 3.56
Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003. Circulation (2003) 3.22
Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA (2004) 3.20
Association of hypoglycemia and cardiac ischemia: a study based on continuous monitoring. Diabetes Care (2003) 3.08
Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Diabetes Care (2004) 3.00
Prolonged diabetes reversal after intraportal xenotransplantation of wild-type porcine islets in immunosuppressed nonhuman primates. Nat Med (2006) 2.83
Effects of cardiac autonomic dysfunction on mortality risk in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Diabetes Care (2010) 2.42
Impact of A1C screening criterion on the diagnosis of pre-diabetes among U.S. adults. Diabetes Care (2010) 2.38
Concern Equilibrative nucleoside transporter 1 (ENT1) regulates postischemic blood flow during acute kidney injury in mice. J Clin Invest (2012) 2.23
Insulin glargine versus sitagliptin in insulin-naive patients with type 2 diabetes mellitus uncontrolled on metformin (EASIE): a multicentre, randomised open-label trial. Lancet (2012) 2.13
Early effect of tidal volume on lung injury biomarkers in surgical patients with healthy lungs. Anesthesiology (2014) 2.06
Prolonged survival of porcine hepatocytes in cynomolgus monkeys. Gastroenterology (2006) 2.04
Spectrum of liver disease in type 2 diabetes and management of patients with diabetes and liver disease. Diabetes Care (2007) 1.95
Sexual dysfunction and cardiac risk (the Second Princeton Consensus Conference). Am J Cardiol (2005) 1.83
Impact of a natural disaster on diabetes: exacerbation of disparities and long-term consequences. Diabetes Care (2009) 1.79
Hypoglycemia, diabetes, and cardiovascular events. Diabetes Care (2010) 1.78
Increasing trends in elderly persons' use of nonvitamin, nonmineral dietary supplements and concurrent use of medications. J Am Diet Assoc (2005) 1.76
Concordance of adherence measurement using self-reported adherence questionnaires and medication monitoring devices. Pharmacoeconomics (2010) 1.70
Insulin resistance and risk of chronic kidney disease in nondiabetic US adults. J Am Soc Nephrol (2003) 1.70
Salicylate (salsalate) in patients with type 2 diabetes: a randomized trial. Ann Intern Med (2013) 1.68
Body weight changes with beta-blocker use: results from GEMINI. Am J Med (2007) 1.60
Correlation between adherence rates measured by MEMS and self-reported questionnaires: a meta-analysis. Health Qual Life Outcomes (2010) 1.60
Cardiovascular effects of insulin sensitizers in diabetes. Curr Opin Investig Drugs (2006) 1.55
Differential effects of beta-blockers on albuminuria in patients with type 2 diabetes. Hypertension (2005) 1.54
Beyond the monofilament for the insensate diabetic foot: a systematic review of randomized trials to prevent the occurrence of plantar foot ulcers in patients with diabetes. Diabetes Care (2011) 1.49
Type 1 diabetes mellitus and cardiovascular disease: a scientific statement from the American Heart Association and American Diabetes Association. Diabetes Care (2014) 1.47
Metabolic memory in diabetes--focus on insulin. Diabetes Metab Res Rev (2005) 1.43
ROLE OF INSULIN SENSITIZERS ON CARDIOVASCULAR RISK FACTORS IN POLYCYSTIC OVARIAN SYNDROME: A META-ANALYSIS. Endocr Pract (2015) 1.39
Type 1 diabetes mellitus and cardiovascular disease: a scientific statement from the American Heart Association and American Diabetes Association. Circulation (2014) 1.32
The Hurricane Katrina aftermath and its impact on diabetes care: observations from "ground zero": lessons in disaster preparedness of people with diabetes. Diabetes Care (2006) 1.31
HPLC-atmospheric pressure chemical ionization MS/MS for quantification of 15-F2t-isoprostane in human urine and plasma. Clin Chem (2007) 1.22
Relationship between HbA1c level and peripheral arterial disease. Diabetes Care (2005) 1.20
Biochemical mechanisms of cyclosporine neurotoxicity. Mol Interv (2004) 1.19
Cardiovascular disease risk of abdominal obesity vs. metabolic abnormalities. Obesity (Silver Spring) (2010) 1.18
Body mass index and risk of ESRD in China. Am J Kidney Dis (2007) 1.15
Impact of hypoglycemia associated with antihyperglycemic medications on vascular risks in veterans with type 2 diabetes. Diabetes Care (2012) 1.15
Narrative review: hepatobiliary disease in type 2 diabetes mellitus. Ann Intern Med (2004) 1.13
Efficacy, tolerability, and safety of a novel once-daily extended-release metformin in patients with type 2 diabetes. Diabetes Care (2006) 1.13
Targeting inflammation using salsalate in patients with type 2 diabetes: effects on flow-mediated dilation (TINSAL-FMD). Diabetes Care (2013) 1.10
Cyclosporine pharmacokinetics and dosing modifications in human immunodeficiency virus-infected liver and kidney transplant recipients. Transplantation (2005) 1.10
Irradiation alters selection for oncogenic mutations in hematopoietic progenitors. Cancer Res (2009) 1.09
Development and validation of an assay for the quantification of 11 nucleotides using LC/LC-electrospray ionization-MS. Anal Biochem (2007) 1.09
Nightmare frequency in sexual assault survivors with PTSD. J Anxiety Disord (2002) 1.04
Metabolic characteristics of imatinib resistance in chronic myeloid leukaemia cells. Br J Pharmacol (2009) 1.04
Therapeutic targets to reduce cardiovascular disease in type 2 diabetes. Nat Rev Drug Discov (2009) 1.04
The burden of hypoglycemia on healthcare utilization, costs, and quality of life among type 2 diabetes mellitus patients. J Diabetes Complications (2012) 1.03
Therapeutic approaches to target inflammation in type 2 diabetes. Clin Chem (2010) 1.03
Overview of metformin: special focus on metformin extended release. Expert Opin Pharmacother (2012) 1.02
Single dose of glutamine enhances myocardial tissue metabolism, glutathione content, and improves myocardial function after ischemia-reperfusion injury. JPEN J Parenter Enteral Nutr (2003) 1.01
Ultrasound-induced mild hyperthermia as a novel approach to increase drug uptake in brain microvessel endothelial cells. Pharm Res (2002) 1.00
Translating the A1C Assay. Diabetes Care (2008) 1.00
Effects of lovastatin on breast cancer cells: a proteo-metabonomic study. Breast Cancer Res (2010) 1.00
Redefining the diagnosis of diabetes using glycated hemoglobin. Diabetes Care (2009) 1.00
Association of DJ-1/PTEN/AKT- and ASK1/p38-mediated cell signalling with ischaemic cardiomyopathy. Cardiovasc Res (2012) 0.99
CYP3A4-transfected Caco-2 cells as a tool for understanding biochemical absorption barriers: studies with sirolimus and midazolam. J Pharmacol Exp Ther (2003) 0.99
Cyclosporine induces endothelial cell release of complement-activating microparticles. J Am Soc Nephrol (2013) 0.99
Pharmacokinetics of mycophenolate mofetil and sirolimus in children. Ther Drug Monit (2008) 0.98
Pharmacokinetic interactions between cyclosporine and protease inhibitors in HIV+ subjects. Drug Metab Pharmacokinet (2003) 0.97
Bile acid sequestrants for lipid and glucose control. Curr Diab Rep (2010) 0.96
Determining standards for laparoscopic proficiency using virtual reality. Am Surg (2005) 0.95
Cardiovascular benefits of exogenous insulin. J Clin Endocrinol Metab (2012) 0.95
Greater free plasma VEGF and lower soluble VEGF receptor-1 in acute mountain sickness. J Appl Physiol (1985) (2005) 0.95
Laparoscopic virtual reality training: are 30 repetitions enough? J Surg Res (2004) 0.95
Hypertension subtype and risk of cardiovascular disease in Chinese adults. Circulation (2008) 0.94
Metabolic profiles in urine reflect nephrotoxicity of sirolimus and cyclosporine following rat kidney transplantation. Nephron Exp Nephrol (2009) 0.94
Differential association of birth weight with cardiovascular risk variables in African-Americans and Whites: the Bogalusa heart study. Ann Epidemiol (2004) 0.93
A sensitive assay for the quantification of morphine and its active metabolites in human plasma and dried blood spots using high-performance liquid chromatography-tandem mass spectrometry. Anal Bioanal Chem (2011) 0.92
Laparoscopic procurement of single versus multiple artery kidney allografts: is long-term graft survival affected? Transplantation (2009) 0.92
Cardiovascular events and insulin therapy: a retrospective cohort analysis. Diabetes Res Clin Pract (2008) 0.92
Polymer-free biolimus a9-coated stent demonstrates more sustained intimal inhibition, improved healing, and reduced inflammation compared with a polymer-coated sirolimus-eluting cypher stent in a porcine model. Circ Cardiovasc Interv (2010) 0.91
Sexual dysfunction and cardiac risk (the Second Princeton Consensus Conference). Am J Cardiol (2005) 0.91
Quantification of 15-F2t-isoprostane in human plasma and urine: results from enzyme-linked immunoassay and liquid chromatography/tandem mass spectrometry cannot be compared. Rapid Commun Mass Spectrom (2011) 0.90
Interpreting mammalian target of rapamycin and cell growth inhibition in a genetically engineered mouse model of Nf1-deficient astrocytes. Mol Cancer Ther (2011) 0.90
Urine metabolites reflect time-dependent effects of cyclosporine and sirolimus on rat kidney function. Chem Res Toxicol (2009) 0.90
Management of diabetes mellitus in patients with cardiovascular disease in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial. Circulation (2010) 0.90
Association of immunosuppressant-induced protein changes in the rat kidney with changes in urine metabolite patterns: a proteo-metabonomic study. J Proteome Res (2010) 0.90
Development and validation of a high-throughput assay for quantification of the proliferation inhibitor ABT-578 using LC/LC-MS/MS in blood and tissue samples. Ther Drug Monit (2005) 0.89
Comparison of lung proteome profiles in two rodent models of pulmonary arterial hypertension. Proteomics (2007) 0.89
Opioid pharmacogenomics using a twin study paradigm: methods and procedures for determining familial aggregation and heritability. Twin Res Hum Genet (2010) 0.89
Emerging technologies: polymer-free phospholipid encapsulated sirolimus nanocarriers for the controlled release of drug from a stent-plus-balloon or a stand-alone balloon catheter. EuroIntervention (2013) 0.88
Serotonin transporter protein in pulmonary hypertensive rats treated with atorvastatin. Am J Physiol Lung Cell Mol Physiol (2007) 0.88
Impact of thiazolidinedione safety warnings on medication use patterns and glycemic control among veterans with diabetes mellitus. J Diabetes Complications (2010) 0.88
Is weight loss possible in patients treated with thiazolidinediones? Experience with a low-calorie diet. Curr Med Res Opin (2003) 0.87
Missing the point: substituting exenatide for nonoptimized insulin: going from bad to worse! Diabetes Care (2007) 0.87
Quantification of isoniazid and acetylisoniazid in rat plasma and alveolar macrophages by liquid chromatography-tandem mass spectrometry with on-line extraction. J Chromatogr B Analyt Technol Biomed Life Sci (2006) 0.87
Immunosuppressant neurotoxicity in rat brain models: oxidative stress and cellular metabolism. Chem Res Toxicol (2010) 0.87
Competitive substrates for P-glycoprotein and organic anion protein transporters differentially reduce blood organ transport of fentanyl and loperamide: pharmacokinetics and pharmacodynamics in Sprague-Dawley rats. Anesth Analg (2009) 0.87
Drugs affecting homocysteine metabolism: impact on cardiovascular risk. Drugs (2002) 0.87
Close association between the reduction in myocardial energy metabolism and infarct size: dose-response assessment of cyclosporine. J Pharmacol Exp Ther (2002) 0.87
Turning glucosuria into a therapy: Efficacy and safety with SGLT2 inhibitors. Curr Diab Rep (2010) 0.87
Predictors of metabolic monitoring among schizophrenia patients with a new episode of second-generation antipsychotic use in the Veterans Health Administration. BMC Psychiatry (2009) 0.86
Barcelona Consensus on Biomarker-Based Immunosuppressive Drugs Management in Solid Organ Transplantation. Ther Drug Monit (2016) 0.86